公开(公告)号：EP3561056B1

公开(公告)日：2023-10-25

申请号：EP17884396.7

申请日：2017-12-21

发明人： NISHIMIYA, Daisuke ,  HASHIMOTO, Ryuji ,  SATO, Toshiyuki ,  KIMURA, Takako ,  YAMASAKI, Atsushi ,  INOUE, Tatsuya

IPC分类号： C12N15/09 ,  A61K38/55 ,  A61K45/00 ,  A61K45/06 ,  A61P9/00 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P43/00 ,  C07K16/38 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  C12Q1/37

公开(公告)号：EP3345927B1

公开(公告)日：2023-01-11

申请号：EP17206143.4

申请日：2006-11-27

发明人： KATO, Shinichiro ,  SOLOFF NUGENT, Rachel ,  YOSHIDA, Hitoshi ,  CROFT, Michael

IPC分类号： C07K16/38

公开(公告)号：EP4023677A1

公开(公告)日：2022-07-06

申请号：EP20858624.8

申请日：2020-08-28

申请人： Suzhou Alphamab Co., Ltd

发明人： XU, Ting ,  WANG, Xiaoxiao ,  FAN, Ying ,  DONG, Yanrong ,  CHEN, Liping ,  JI, Jianyun

IPC分类号： C07K16/38 ,  A61K39/395 ,  A61P7/04

摘要： Disclosed are a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.

公开(公告)号：EP2588499B1

公开(公告)日：2020-04-08

申请号：EP11729297.9

申请日：2011-06-30

申请人： Novo Nordisk A/S

发明人： HILDEN, Ida ,  CLAUSEN, Jes Thorn ,  PETERSEN, Lars Christian ,  SØRENSEN, Brit Binow ,  PETERSEN, Helle Heibroch

IPC分类号： C07K16/38 ,  A61K39/395 ,  A61P7/04

公开(公告)号：EP3117837B1

公开(公告)日：2019-05-22

申请号：EP16180643.5

申请日：2013-08-28

申请人： Bayer HealthCare LLC

发明人： MA, Xinghang ,  XIANG, Jun

IPC分类号： A61K39/395 ,  C07K16/38

公开(公告)号：EP3473650A1

公开(公告)日：2019-04-24

申请号：EP17197139.3

申请日：2017-10-18

申请人： Universitätsklinikum Jena ,  Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut

发明人： Kiehntopf, Dr. Michael ,  Schmerler, Dr. Diana ,  Kaczmarek, Anika ,  Horn, Dr. Uwe

IPC分类号： C07K16/38

摘要： The present invention relates to an antibody that binds specifically to CAAP47/48 fragments, allowing for the highly specific detection of CAAP47/48 for diagnostic purposes.
The invention further relates to a vector and kit comprising said antibody. The antibody can be used for determining and/or differentially diagnosing a CAAP47/48 correlated disease. For example, the antibody according to the invention can be used for determining whether an infection is of bacterial or non-bacterial origin.
The present invention also relates to a method for determining in a patient whether an infection is of bacterial or non-bacterial origin using the antibody according to the invention. Said method comprises determining the concentration of CAAP47/48 in a sample that has been taken from said patient, and determining whether said patient suffers from an infection of bacterial or non-bacterial origin based on the concentration of CAAP47/48 and designating the infection as of bacterial or non-bacterial origin.
Another aspect of the present invention is a method of monitoring the treatment of a patient with an antimicrobial drug, comprising determining the level of CAAP47/48 in a sample taking from said patient by using the antibody according to the invention and evaluating the effect of treatment with said antimicrobial drug based on the comparison of the levels of CAAP47/48 to reference values and the level of CAAP47/48 at different time-points in the same patient.

公开(公告)号：EP3345615A1

公开(公告)日：2018-07-11

申请号：EP17172199.6

申请日：2011-03-01

申请人： Bayer Healthcare LLC

发明人： Scholz, Peter ,  Wang, Zhuozhi ,  PAN, Junliang ,  Grudzinska, Joanna ,  Votsmeier, Christian ,  Tebbe, Jan ,  Birkenfeld, Jörg ,  Wobst, Nina ,  Brückner, Simone ,  Steinig, Susanne

IPC分类号： A61K39/00 ,  C07K16/38 ,  A61P7/04

摘要： Monoclonal antibodies to human tissue factor pathway inhibitor (TFPI) are provided. Further provided are the isolated nucleic acid molecules encoding the same. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treatment of genetic and acquired deficiencies or defects in coagulations such as hemophilia A and B are also described. Also described are methods for shortening the bleeding time by administering an anti-TFPI monoclonal antibody to a patient in need thereof. Methods for producing a monoclonal antibody that binds human TFPI according to the present invention are also provided.
In some embodiments, the monoclonal antibodies to TFPI provided have been optimized, for example to have increased affinity or increased functional activity.

公开(公告)号：EP3337827A2

公开(公告)日：2018-06-27

申请号：EP16763319.7

申请日：2016-08-10

申请人： Pfizer Inc.

发明人： APGAR, James R. ,  BENARD, Susan ,  CARVEN, Gregory J. ,  HETT, Sunita R. ,  HOLSTI, Matthew ,  JASUJA, Reema ,  JIN, Macy ,  JUO, Zong Sean ,  PITTMAN, Debra ,  STAHL, Mark

IPC分类号： C07K16/38 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/38 ,  A61K38/4846 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/55522 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y304/21021

摘要： The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

公开(公告)号：EP3337822A1

公开(公告)日：2018-06-27

申请号：EP16757810.3

申请日：2016-08-18

申请人： Rutgers, The State University of New Jersey

发明人： ANDERSON, Stephen ,  CAMPBELL, Elliot

IPC分类号： C07K16/20 ,  C07K16/38 ,  C07K16/00 ,  C07K14/00

CPC分类号： C07K16/1045 ,  A61K9/0019 ,  C07K1/047 ,  C07K16/00 ,  C07K16/065 ,  C07K16/205 ,  C07K16/38 ,  C07K2317/14 ,  C07K2317/33 ,  C07K2317/92 ,  Y02A50/58

摘要： The invention describes a method of generating antibodies to a mixture of peptidogenic proteins wherein the peptidogenic protein has altered conformational dynamics as compared to a starting protein and wherein the peptidogenic protein has a similar conformation to the starting protein. The peptidogenic proteins can be used to induce an immune response, which can lead to the generation of antibodies and/or can be used to vaccinate a mammal.

公开(公告)号：EP3334820A1

公开(公告)日：2018-06-20

申请号：EP16834685.6

申请日：2016-08-12

申请人： Beihao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. ,  Peking University ,  Hong Guan Ltd.

发明人： DENG, Hongkui ,  YANG, Yang ,  LIU, Bei ,  XU, Jun

IPC分类号： C12N5/00 ,  C07K14/54 ,  C07K14/715 ,  C12N5/07 ,  C12N5/074 ,  C12N5/0789 ,  C12N5/0797 ,  C12N5/095 ,  C07K16/38 ,  C07K16/40

CPC分类号： C12N5/0696 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2217/00 ,  A01K2227/105 ,  A61K35/545 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0605 ,  C12N5/0606 ,  C12N15/873 ,  C12N2501/15 ,  C12N2501/20 ,  C12N2501/2306 ,  C12N2501/2311 ,  C12N2501/2327 ,  C12N2501/2331 ,  C12N2501/235 ,  C12N2501/237 ,  C12N2501/603 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2510/00

摘要： Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methods of extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period of time to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a number of applications, including but not limited to cell therapy and tissue engineering.